Protein Sequencing Market Analysis and Forecast to 2033: By Technology (Edman Degradation, Mass Spectrometry, N-terminal Sequencing, Amino Acid Analysis, Next-Generation Sequencing for Proteomics), Component (Instruments, Reagents, Software for Data Analy

Protein Sequencing Market Analysis and Forecast to 2033: By Technology (Edman Degradation, Mass Spectrometry, N-terminal Sequencing, Amino Acid Analysis, Next-Generation Sequencing for Proteomics), Component (Instruments, Reagents, Software for Data Analysis, Sequencing Services), Application (Biotherapeutics Characterization, Proteomics Research, Genetic Engineering, Drug Discovery and Development, Disease Diagnosis, Other Life Sciences Applications), End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations, Clinical Laboratories), Platform (Liquid Chromatography, Capillary Electrophoresis, Protein Microarrays, Protein Fractionation), Protein Type (Monoclonal Antibodies, Enzymes, Hormones, Structural Proteins, Others), and Region

The protein sequencing market size was USD 1,654.5 million in 2023 and is anticipated to reach USD 3,263.1 million in 2033, growing at a rate of 7.1% from 2024 to 2033.

Protein sequencing involves identifying the exact sequence of amino acids within a protein molecule, which is crucial for understanding its function and role in biological systems. This technique is fundamental in molecular biology and biochemistry, as it reveals the specific order of amino acids, which are the basic components of proteins, arranged in a linear sequence known as the protein's primary structure. Understanding the primary structure helps to understand the genetic instructions of proteins, and it's extremely important across many fields of science. Protein sequencing can be categorized into three main methods: investigating the N-terminus, exploring the C-terminus (limited methods, typically involving carboxypeptidases), and breaking down polypeptides into peptides.

Market Trends and Drivers

The Rising Adoption Of Mass Spectrometry For Protein Sequencing

The adoption of mass spectrometry for protein sequencing represents a significant trend in the protein sequencing market, driven by several key factors. This include mass spectrometry offers unmatched sensitivity and accuracy in protein identification, enabling researchers to detect and characterize proteins even at low concentrations within complex biological samples. In studying diseases, it's essential to detect even small changes in how proteins are made or altered because these changes can be really important for diagnosing and treating the illness..

Further, mass spectrometry allows for de novo protein sequencing, eliminating the reliance on existing genomic databases. This expands the scope of proteomic analysis, facilitating the discovery of novel proteins and post-translational modifications not cataloged in databases. Consequently, researchers can explore the full complexity of the proteome, uncovering previously unknown biological mechanisms and various physiological and pathological processes.

For instance., In March 2023, Bruker Corporation announced significant bioinformatics launches at the 19th US HUPO conference. These launches include the introduction of a novel de novo sequencing algorithm developed in collaboration with Rapid Novor Inc. The algorithm, called PaSER™ Novor, aims to enhance accuracy and speed for immunopeptidomics, particularly beneficial for analyzing small tumor biopsy samples.

Key Players Are Focusing Towards Manufacturing Integrated, Automated Sequencing Systems

The protein sequencing market is experiencing a notable trend towards the development of integrated and automated sequencing systems, driven by advancements in technology and a growing demand for efficient and accurate protein analysis. In March 2022, Thermo Fisher Scientific unveiled the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, a groundbreaking automated NGS platform designed for clinical laboratories. This system, delivering results within a single day, caters to both diagnostic testing and clinical research needs, streamlining processes and enhancing efficiency in protein sequencing. Moreover, in December 2022, Quantum-Si Incorporated introduced Platinum, the world's first next-generation single-molecule protein sequencing platform. This innovation represents a significant leap forward in automated protein sequencing technology, offering enhanced precision and sensitivity in protein analysis.

Furthermore, various companies are leveraging partnerships and collaborations to enhance their sequencing capabilities. For instance, in January 2022, Illumina, Inc. announced a co-development agreement with SomaLogic to integrate the SomaScan Proteomics Assay onto Illumina's high-throughput NGS platforms. This collaboration aims to accelerate the pace of proteomic research by combining Illumina's scale and speed with SomaLogic's innovative assay technology. Additionally, companies like Bruker Corporation are pushing the boundaries of sensitivity and performance in protein analysis. In June 2023, Bruker launched the timsTOF Ultra mass spectrometer, featuring transformative sensitivity enhancements on the 4D-Proteomics platform. This instrument incorporates advanced ionization and ion mobility technologies, facilitating comprehensive protein characterization with unparalleled accuracy and efficiency.

The Rise Of Personalized Medicine And The Growing Emphasis On Targeted Therapies Are Driving The Adoption Of Protein Sequencing

The emergence of personalized medicine is poised to significantly propel the growth of the protein sequencing market as personalized medicine becomes increasingly prevalent, there is a growing demand for precise and comprehensive analysis of an individual's proteome. Protein sequencing plays a essential role in personalized medicine by enabling the precise analysis of an individual's proteome, identifying specific protein biomarkers and mutations associated with their health or disease condition. This information guides the development of personalized diagnostics for early disease detection and monitoring, as well as the design of targeted therapies tailored to the unique biological characteristics of each patient, thereby maximizing treatment efficacy and minimizing adverse reactions.

Moreover, as the focus shifts towards targeted therapies designed to address the underlying molecular mechanisms of diseases, protein sequencing becomes even more essential. By explaining mutant protein sequences, protein sequencing provides essential understandings into the molecular basis of various diseases, guiding the design and development of precise therapeutic interventions. Furthermore, the increasing integration of genetic and proteomic data in personalized medicine further underlines the importance of protein sequencing.

Increasing Investment In Proteomic Research

Investments in proteomic research enable the development of advanced technologies and methodologies for studying proteins at a large scale. Proteomic research aims to understand the structure, function, and interactions of proteins within biological systems. This includes identifying and quantifying proteins, analyzing post-translational modifications, and elucidating protein-protein interactions. Additionally, an article from Forbes in 2021 highlights the potential of proteomics, stating that highly respected medical research facility the Baker Institute found proteomics provides 1000X more information than DNA.. This wealth of information provided by proteomics offers valuable insights into various biological processes, disease mechanisms, and potential drug targets. By investing in proteomic research, scientists can harness this wealth of information to enhance protein sequencing techniques.

Further the pharmaceutical and biotech companies, recognizing the potential of proteomics, have increased their investment in research and development in this area. Reports from companies like Novartis highlight successful proteomics programs that have produced new drug candidates and biomarkers, featuring the tangible returns on investment in proteomic research. Similarly, according to a report by Novo Holdings in 2023, a $40 million investment was made in Evosep, a bioscience company leading the standardization of proteomics for clinical use.

Market Restraints & Challenges

High Costs Associated with Protein Sequencing Technologies

One significant restraint in the global protein sequencing market is the high costs associated with protein sequencing technologies. Protein sequencing involves determining the precise order of amino acids within a protein molecule, which is essential for understanding its structure, function, and interactions. While protein sequencing plays a crucial role in various fields such as biotechnology, pharmaceuticals, and medical research, the expenses involved in acquiring and operating protein sequencing equipment, reagents, and software can be prohibitive for many organizations. The initial investment required to purchase protein sequencing equipment and setup laboratories can be substantial, posing a significant financial barrier to entry for smaller research institutions, academic laboratories, and startups. High-end protein sequencers, such as mass spectrometers and next-generation sequencing platforms, come with hefty price tags, often exceeding hundreds of thousands to millions of dollars. For instance, a high-end mass spectrometer capable of advanced protein analysis can cost over $500,000. Additionally, the ongoing costs associated with maintaining, calibrating, and upgrading these instruments further add to the financial burden.

In addition to equipment costs, there are significant operational expenses associated with protein sequencing, including reagents, consumables, and specialized software for data analysis and interpretation. High-quality reagents and consumables are essential for accurate and reliable protein sequencing results but can contribute substantially to overall project costs. Moreover, the complexity of protein sequencing workflows and data analysis requires skilled personnel, further increasing labor costs and resource requirements.

Volatility in Raw Materials Prices

The high costs associated with protein sequencing technologies limit the affordability and accessibility of protein sequencing services for researchers and organizations with limited financial resources. This disparity in access to protein sequencing capabilities hinders scientific progress and innovation, particularly in resource-constrained environment where research funding is limited. As a result, many promising research projects may be delayed or abandoned due to financial constraints, impeding advancements in areas such as drug discovery, biomarker identification, and personalized medicine. Furthermore, for businesses and institutions considering investments in protein sequencing technologies, there are inherent risks and uncertainties regarding the return on investment (ROI) and long-term sustainability. The substantial capital expenditure required for acquiring protein sequencing equipment represents a significant financial commitment, with no guarantee of immediate returns or profitability. Moreover, rapid technological advancements and evolving market dynamics pose risks of equipment obsolescence and depreciation, further complicating investment decisions.

Ultimately, while advancements in technology and economies of scale may lead to cost reductions over time, addressing the affordability and accessibility challenges of protein sequencing remains crucial for fostering widespread adoption and utilization of this critical analytical technique in scientific research and biomedical applications. Efforts to mitigate the financial barriers to entry, such as collaborative research initiatives, cost-sharing arrangements, and government funding support, are essential for overcoming this restraint and unlocking the full potential of protein sequencing in advancing scientific knowledge and improving human health.

COVID-19 Impact

Pre-COVID-19 Pandemic Scenario

Before the COVID-19 pandemic, the field of protein sequencing was advancing steadily and finding widespread use across various scientific domains. Throughout 2018 and 2019, researchers heavily relied on protein sequencing techniques for a myriad of scientific inquiries. Notably, in 2019, a significant study utilized protein sequencing to perform a comparative analysis between HIV-1, the virus causing AIDS, and other diseases. This study highlighted the versatility and importance of protein sequencing in biomedical research. It demonstrated how protein sequencing could offer valuable insights into the intricate molecular mechanisms that drive complex diseases. By deciphering the protein compositions and interactions associated with different pathogens, researchers could gain a deeper understanding of their pathogenicity, transmission, and potential vulnerabilities. This comparative analysis underscored the pivotal role of protein sequencing in elucidating disease mechanisms and informing the development of targeted therapeutic interventions. Therefore, prior to the COVID-19 pandemic, protein sequencing stood as a cornerstone technology in biomedical research, facilitating critical discoveries and advancements in understanding disease biology.

COVID-19 Pandemic Scenario

The COVID-19 pandemic unleashed a profound impact on the medical industry, triggering a wave of transformative changes that reverberated across various sectors, including protein sequencing. Throughout 2020 and 2021, the pandemic spurred unprecedented demand for innovative solutions to combat the virus, leading to significant adaptations and advancements in medical technologies. In the realm of protein sequencing, the COVID-19 pandemic prompted a paradigm shift in research priorities and methodologies. With the urgent need to understand the structure and function of the novel coronavirus, scientists intensified their efforts to unravel the molecular complexities of SARS-CoV-2, the virus responsible for COVID-19. Protein sequencing emerged as a critical tool in this endeavor, enabling researchers to decipher the genetic code of the virus and analyze its protein composition with unprecedented precision. The recent study from the Indian Institute of Science (IISc), published in the Journal of Proteome Research, epitomizes this shift in focus, as researchers conducted a comprehensive "proteo-genomic" investigation of SARS-CoV-2 isolates. This study not only identified multiple mutations and unique proteins in the viral isolates but also shed light on the host's immune response by examining host proteins.

Post-COVID-19 Pandemic Scenario

Post-COVID-19, the impact on protein sequencing continues to be profound. With the lessons learned during the pandemic, there has been a surge in investment and research into protein sequencing technologies and applications. The demand for high-throughput sequencing methods has intensified, driven by the need for rapid and accurate analysis in various fields, including drug development, personalized medicine, and understanding complex diseases such as cancer and neurodegenerative disorders. Collaborative efforts among researchers have strengthened, leading to the development of innovative approaches and tools for protein analysis. Moreover, the integration of artificial intelligence and machine learning algorithms into protein sequencing workflows has enhanced data analysis and interpretation, accelerating discoveries. As societies adapt to the post-pandemic world, the role of protein sequencing in advancing biomedical research and addressing global health challenges has become more prominent than ever, paving the way for ground-breaking discoveries and therapeutic interventions. Post-COVID-19, the advancements made in protein sequencing technology and its applications are likely to continue shaping research across various disciplines, driving progress in personalized medicine, biotechnology, and understanding complex diseases beyond infectious agents. The pandemic served as a catalyst for innovation in protein sequencing, emphasizing its critical role in addressing global health challenges.

Protein Sequencing Segmental Overview

The protein sequencing market is segmented into technology, application, end-user, components, protein type, platform, and region.

Protein Sequencing Market By Technology

Based on technology, the market is segmented into mass spectrometry, degradation, n-terminal sequencing, amino acid analysis, and next-generation sequencing for proteomics.

The mass spectrometry segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 1,189.2 Million in 2023 and it is anticipated to grow further by 2033, at a CAGR of 7.2% during the forecast period. Likewise, the mass spectrometry segment is anticipated to witness the fastest growth during the forecast period. The factors such as the increasing demand for advanced proteomic analysis tools in biomedical research and clinical diagnostics will propel the mass spectrometry segment in the protein sequencing market. As the understanding of the human proteome deepens and the importance of proteins in health and disease becomes more evident, there is a growing need for advanced technologies capable of characterizing complex protein samples. Mass spectrometry-based proteomics enables researchers to study protein-protein interactions, post-translational modifications, and protein isoforms, leading to the discovery of disease biomarkers, drug targets, and therapeutic proteins.

Protein Sequencing Market By Application

Based on application, the market is segmented into biotherapeutics characterization, proteomics research, genetic engineering, drug discovery and development, disease diagnosis,, and other life sciences applications.

The biotherapeutics characterization segment is anticipated to dominate the market during the forecast period. The segment was valued at USD  776.2 million in 2023 and it is anticipated to grow further to USD 1,557.8 million by 2033, at a CAGR of 7.3% during the forecast period. The growth of the biotherapeutics characterization segment is driven by several factors. Firstly, pharmaceutical and biotechnology companies are increasingly focusing on target-based drug development, which requires a thorough understanding of proteins and their functions. Secondly, advancements in technology, particularly in clinical mass spectrometry and analytical techniques, have advanced significantly, allowing for more accurate and efficient protein sequencing. Lastly, there is increasing public-private financial support for proteomic research, which is driving the growth of the protein sequencing market.

Protein Sequencing Market By End-User

Based on end-user, the market is segmented into academic and research institutes, pharmaceutical and biotechnology, contract research organizations, and clinical laboratories.

The academic and research institutes segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 750.2 Million in 2023 and it is anticipated to grow further to USD 1,490.5 Million by 2033, at a CAGR of 7.2% during the forecast period. One of the primary drivers of the academic and research institutes segment is the increasing demand for protein sequencing technologies to support basic research and translational studies. Researchers in academic and research institutes are engaged in a wide range of biological and biomedical research projects that require protein sequencing capabilities. These projects span various disciplines, including molecular biology, genetics, biochemistry, pharmacology, and systems biology, and often involve the identification, characterization, and functional analysis of proteins. Protein sequencing technologies, such as mass spectrometry, Edman degradation, and next-generation sequencing, are indispensable tools for researchers seeking to articulate the structure, function, and interactions of proteins in health and disease.

Protein Sequencing Market By Component

Based on components, the market is segmented into reagents and consumables, instruments, software for data analysis, and sequencing services.

The reagents and consumables segment is anticipated to dominate the market during the forecast period. The segment was valued at USD  692.5 million in 2023 and it is anticipated to grow further to USD 1,386.5 million by 2033, at a CAGR of 7.3% during the forecast period. Technological advancements in protein sequencing technologies have stimulated the development of innovative reagents and consumables boasting enhanced performance, sensitivity, and specificity. Manufacturers continuously introduce novel reagents and kits optimized for specific protein sequencing applications, such as mass spectrometry-based proteomics, next-generation sequencing, and antibody-based assays. These advancements bolster the efficiency and reproducibility of protein sequencing experiments, fueling the adoption of reagents and consumables across research laboratories, academic institutions, and biotechnology firms.

Protein Sequencing Market By Protein Type

Based on protein type, the market is segmented into monoclonal antibodies, enzymes, hormones, structural proteins, and others.

The monoclonal antibodies segment is anticipated to dominate the market during the forecast period. The segment was valued at USD  635.0 Million in 2023 and it is anticipated to grow further to USD 1,280.9 Million by 2033, at a CAGR of 7.3% during the forecast period. The monoclonal antibody segment has witnessed significant growth within the protein sequencing market, primarily owing to its unique characteristics and diverse applications in biomedical research and therapeutics. It offer exceptional selectivity, enabling researchers to precisely target and isolate specific proteins of interest from complex biological samples. This selectivity is crucial for accurate protein sequencing, as it allows for the identification and characterization of individual proteins within a mixture, even at low concentrations. Further, the widespread adoption of monoclonal antibodies in biomedical research and clinical diagnostics has fueled the demand for advanced protein sequencing technologies that can effectively analyze antibody-protein interactions and elucidate complex protein structures. As monoclonal antibodies continue to play a pivotal role in the development of targeted therapeutics and personalized medicine. There is a growing need for innovative protein sequencing solutions that can facilitate the characterization and optimization of antibody-based drugs. Hence aforementioned factors fuel the segmental as well as market growth during the forecast period.

Protein Sequencing Market By Platform

Based on platform, the market is segmented into liquid chromatography, capillary electrophoresis, protein microarrays, and protein fractionation.

The liquid chromatography segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 1,090.2 Million in 2023 and it is anticipated to grow further to USD 2,178.0 Million by 2033, at a CAGR of 7.2% during the forecast period. The growth of the liquid chromatography platform in the protein sequencing market can be attributed to several key factors. Advancements in chromatography technology have significantly improved the efficiency and accuracy of protein sequencing processes. Liquid chromatography techniques, such as high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UHPLC), offer high resolution and sensitivity, enabling the separation and analysis of complex protein mixtures with greater precision. This enhanced capability is crucial for identifying and characterizing proteins in various biological samples, driving the adoption of liquid chromatography in protein sequencing workflows. For instance., the innovative Agilent portfolio of liquid chromatography/mass spectrometry (LC/MS) instruments offers unparalleled performance in HPLC separation coupled with the sensitivity and specificity of mass spectrometry, driving advancements in the liquid chromatography segment of the protein sequencing market.

Protein Sequencing Market By Region

Based on region, the market is studied across North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.

The North America region is anticipated to dominate the market during the forecast period. The region was valued at USD 640.1 Million in 2023 and it is anticipated to grow further to USD 1,271.3 Million by 2033, at a CAGR of 7.2% during the forecast period. This growth is driven by the presence of well-established academic institutions and research centers in North America, coupled with growing opportunities for research and development (R&D) funding, contribute significantly to the region's leadership in protein sequencing. Government support for organizations engaged in this field is robust. UniProt serves as a prime example, providing free access to resources for protein sequencing and functional information. Supported by various government institutions such as the National Eye Institute (NEI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Human Genome Research Institute (NHGRI), UniProt plays a pivotal role in advancing protein research without cost barriers. Additionally, substantial investments in proteomics and genomics research, the presence of key industry players, and a thriving biopharmaceutical sector. For instance., in March 2022, a researcher from the University of North Texas Department of Biomedical Engineering was awarded a USD 1.5 million Maximizing Investigators' Research Award (MIRA) from the National Institutes of Health (NIH) to investigate protein and cellular engineering. This funding enables the researcher to explore novel functions and characteristics in biological proteins, aiming to create innovative biological behaviors.

Key Players

The market includes players such as Agilent Technologies (USA), Thermo Fisher Scientific (USA), Shimadzu Corp (JPN), Waters Corp. (USA), Bio-Rad Laboratories (USA), Bruker Corporation (USA), Rapid Novor Inc. (CAN), Bioinformatics Solutions Inc., JEOL Ltd., Bio-Techne, Illumina, Inc., GenScript, Promega Corporation, Takara Bio Inc., New England Biolabs, Merck KGaA, PerkinElmer (Revvity), and Danaher Corporation.

Recent Developments

In April 2024, Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium (CTS OpTmizer One SFM), a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion.

In April 2024, Agilent Technologies Inc.  announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of ownership, and improve the overall efficiency within the laboratory.

In April 2024, RevolKa Ltd., have partnered with the La Jolla Institute for Immunology (LJI), led by Erica Saphire, President & CEO, to work together on researching and developing antigens for new vaccines. This collaboration aims to address medical needs in infectious diseases by providing innovative solutions. RevolKa's technology, aiProtein®, combines directed protein evolution with artificial intelligence (AI). By combining LJI's expertise in immunology with RevolKa's AI-driven protein engineering, they aim to create more effective vaccines. The specific details of the collaboration and financial arrangements were not disclosed.

In March 2024, Tierra Biosciences, a startup based in California, has successfully completed a Series A funding round worth $11.4 million. Material Impact led the round, which builds upon the company's previous seed funding of $6 million and grant funding of over $7 million. Both new and existing investors, including Prosus Ventures, In-Q-Tel (IQT), Hillspire, Freeflow Ventures, Creative Ventures, and Social Capital, contributed to this round.

In March 2024, Alamar Biosciences, a company specializing in protein sequencing, has secured $128 million in venture capital funding to support the widespread release of its newly developed research hardware introduced over the past year.The funding, known as a series C round, comprises an initial $100 million investment, with the remaining $28 million anticipated to be finalized within the next month, as per the company's statement. Sands Capital led the funding round, with support from other undisclosed investors.

In November 2023, Dutch biotech startup Cradle has secured a $24 million Series A funding round led by Index Ventures, along with participation from Kindred Capital and angel investors. Cradle's protein engineering technology is currently employed in twelve projects with industry partners, demonstrating the ability to cut in half the time required for research and development (R&D) to advance products to clinical testing. The funding will enable Cradle to expand its team, which currently consists of 20 employees.

In July 2023, Platinum®, Quantum-Si's latest protein sequencer, revolutionizes protein sequencing by offering a user-friendly process, compact size, and the ability to analyze single molecules.

Protein Sequencing Market Report Coverage

The report offers a comprehensive quantitative as well as qualitative analysis of the current Protein Sequencing Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.

The report also covers qualitative as well as quantitative analysis of Protein Sequencing Market in terms of revenue ($Million).

Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Protein Sequencing Industry.

A thorough analysis of market trends and restraints is provided.

By region as well as country market analysis is also presented in this report.

Analytical depiction of the Protein Sequencing Market along with the current trends and future estimations to depict imminent investment pockets. The overall Protein Sequencing industry opportunity is examined by understanding profitable trends to gain a stronger foothold.

Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Protein Sequencing Market are also analyzed.

Frequently Asked Questions

Q1. How big is the Protein Sequencing Market?

Ans: The Protein Sequencing market size was USD 1,654.5 million in 2023 and is anticipated to reach USD 3,263.1 million in 2033, growing at a rate of 7.1% from 2024 to 2033.

Q2. What is the Protein Sequencing Market growth rate?

Ans. The growth rate of the Protein Sequencing Market is 7.1%

Q3. Which region holds a major market share for the market?

Ans. North American holds a major market share in 2023.

Q4. Which segment accounted for the largest Protein Sequencing Market share?

Ans. Based on end-user, the market is segmented into academic and research institutes, pharmaceutical and biotechnology, contract research organizations, and clinical laboratories. By end-user, the academic and research institutes segment accounted for the largest Protein Sequencing Market share in 2023.

Q5. Who are the key players in the Protein Sequencing Market?

Ans. The Protein Sequencing Market report includes players such as Agilent Technologies (USA), Thermo Fisher Scientific (USA), Shimadzu Corp (JPN), Waters Corp. (USA), Bio-Rad Laboratories (USA), Bruker Corporation (USA), Rapid Novor Inc. (CAN), Bioinformatics Solutions Inc., JEOL Ltd., Bio-Techne, Illumina, Inc., GenScript, Promega Corporation, Takara Bio Inc., New England Biolabs, Merck KGaA, PerkinElmer (Revvity), and Danaher Corporation.

Q6. What is the factor driving the Protein Sequencing Market growth?

Ans. The major factor driving the growth of the market are the Rising Adoption Of Mass Spectrometry